期刊文献+

氟喹诺酮类药物所致尖端扭转型室性心动过速 被引量:18

Fluoroquinolone-induced torsade de pointes
原文传递
导出
摘要 氟喹诺酮类常用药物中左氧氟沙星、环丙沙星、加替沙星和莫西沙星等可以引起尖端扭转型室性心动过速(TdP)。TdP的临床表现为眩晕、昏厥甚至心搏停止,心电图可见QT间期延长及TdP。其发生机制尚不明确,可能与抑制心肌细胞K+离子通道,使K+外流受阻有关。氟喹诺酮类常用药物所致TdP的危险因素有女性、高龄、器质性心脏病(特别是充血性心力衰竭、QT间期延长、心动过缓)、肝肾功能损害、低钾低镁血症,以及合用可以引起QT间期延长的药物等。一旦患者出现QT间期延长及TdP应立即停药,补充钾和镁抑制早期后除极,也可采用人工临时心脏起搏或异丙肾上腺素提高基础心率。意识丧失和心室颤动者,可进行体外电复律。 Fluoroquinolone antibacterials levofloxacin,ciprofloxacin,gatifloxacin and moxifloxacin have been reported to cause torsades de pointes(TdP).Clinical manifestations of TdP are dizziness,fainting,or even cardiac arrest.QT interval prolongation and TdP are visible on the electrocardiogram(ECG).The mechanism of TdP is unclear,it may be associated with inhibition of cardiac K+ channels and blocking of K+ outflow.The risk factors for causing TdP are female,advanced age,underlying organic heart disease(especially congestive heart failure,QT interval prolongation and bradycardia),liver and kidney dysfunction,hypokalemia,and hypomagnesemia,as well as combined use with other drugs that can cause QT interval prolongation.Once a patient develops to QT interval prolongation and TdP,the causative agent should be discontinued immediately.Potassium and magnesium supplements are given to inhibit the early after-depolarization.Artificial temporary cardiac pacing or isoprenaline is used to maintain normal heart rate.For the unconscious patient with ventricular fibrillation,external electrical cardioversion could be carried out.
出处 《药物不良反应杂志》 2011年第2期95-98,共4页 Adverse Drug Reactions Journal
关键词 氟喹诺酮 尖端扭转型室性心动过速 fluoroquinolone torsade de pointes
  • 相关文献

参考文献16

  • 1卫生部合理用药专家委员会.中国医师药师临床用药指南[M].重庆:重庆出版集团重庆出版社,2009:700-701.
  • 2Frothingham R.Quinolone safety and efficacy[J].Emerg Infect Dis,2005,11(6):985-987.
  • 3Prabhakar M,Krahn AD.Ciprofloxacin-induced acquired long QT syndrome[J].Heart Rhythm,2004,1(5):624-626.
  • 4Flanagan MC,Mitchell ES,Haigney MCP.Ciprofloxacininduced torsade de pointes[J].Int J Cardiol,2006,113(2):239-241.
  • 5Daya SK,Gowda RM,Khan IA.Ciprofloxacin-and hypocalcemia-induced torsade de pointes triggered by hemodialysis[J].Am J Ther,2004,11(1):77-79.
  • 6Amankwa K,Krishnan SC,Tisdale JE.Torsades de pointes associated with fluoroquinolones:importance of concomitant risk factors[J].Clin Pharmacol Ther,2004,75(3):242-247.
  • 7Gandhi PJ,Menezes PA,Vu HT,et al.Fluconazole-and levofloxacin-induced torsades de pointes in an intensive care unit patient[J].Am J Health Syst Pharm,2003,60(23):2479-2483.
  • 8Fteha A,Fteha E,Haq S,et al.Gatifloxacin induced torsades de pointes[J].Pacing Clin Electrophysiol,2004,27(10):1449-1450.
  • 9Bertino JS Jr,Owens RC Jr,Carnes TD,et al.Gatifloxacin-associated corrected QT interval prolongation,torsades de pointes,and ventricular fibrillation in patients with known risk factors[J].Clin Infect Dis,2002,34(6):861-863.
  • 10Altin T,Ozcan O,Turhan S,et al.Torsade de pointes associated with moxifloxacin:a rare but potentially fatal adverse event[J].Can J Cardiol,2007,23(11):907-908.

二级参考文献52

  • 1成建华.非抗心律失常药的致心律失常作用及相关危险因子[J].中国新药与临床杂志,2004,23(10):713-718. 被引量:5
  • 2Mitcheson JS,Chen J,Lin M,et al. A structural basis for drug-induced long QT syndrome[J]. Proc Natl Acad Sci USA, 2000, 97:12 329- 12 333.
  • 3De Bruin ML, Pettersson M, Meyboom RH, et al. Anti- HERG activity and the risk of drug-induced arrhythmias and sudden death[J]. Eur Heart J,2005, 26:590 - 597.
  • 4Yap YG, Camm AJ. Drug induced QT prolongation and torsades de pointes[J]. Heart, 2003, 89:1 363 - 1 372.
  • 5Zelter D, Justo D, Halkin A, et al. Torsade de pointes due to noncardiac drugs: most patients have easily identifiable risk factors[J]. Medicine (Baltimore), 2003, 82:282 -290.
  • 6Tamargo J. Drug-induced Torsade de Pointes: From molecular biology to bedside [ J ]. Jpn J Pharmacol, 2000, 83 (1) : 1 - 19.
  • 7Torp-Pedersen C, Moller M, Bloch-Thomsen PE, et al. Dofetilide in patients with congestive heart failure and left ventricular dysfunction. Danish Investigations of Arrhythmia and Mortality on Dofetilide Study Group[J]. N Engl J Med, 1999, 341:857 -865.
  • 8Stambler BS, Wood MA, Ellenbogen KA, et al. Efficacy and safety of repeated intravenous doses of ibutilide for rapid conversion of atrial flutter or fibrillation[J]. Ibutilide repeat Dose Study Investigators Circulation;1996, 94:1 613 - 1 621.
  • 9Katrisis D. Quinolones [ J ]. Pacing Clin Electriophysiol, 2003, 26 (12) : 2 317.
  • 10Owens RC, Ambrose PG. Torsades de pointes associated with fluoroquinolone [ J ]. Pharmacotherapy, 2002, 22: 663.

共引文献375

同被引文献152

引证文献18

二级引证文献86

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部